Oncology Biomarkers: Global Markets

Jul 2023| BIO244A| BCC Publishing

Report Highlights

The global oncology biomarkers market reached $15.5 billion in 2022, should reach $17.6 billion by 2023 and $35.2 billion by 2028 with a compound annual growth rate (CAGR) of 14.9% during the forecast period of 2023-2028.

Report Includes

  • 21 data tables and 60 additional tables
  • An in-depth analysis of the global oncology biomarkers market
  • Analyses of global market trends, with data from 2020, 2021, 2022, and projections of compound annual growth rates (CAGRs) through 2028
  • Characterization and quantification of biomarkers market by type, profiling technology, application, cancer type, and region
  • Discussion on market drivers, challenges and key market strategies and trends
  • Information on emerging products and technologies, new analytical platforms, novel immunoassays, and bioinformatics tools and discussion on the use of biomarkers in cancer drug development
  • Profiles of the competitive landscape with an overview of competitor growth strategies and opportunities
  • Company profiles of major players within the industry, including Abbott, F. Hoffmann-La Roche Ltd., Merck KGaA, Siemens Healthineers AG, and Thermo Fisher Scientific Inc.

Report Scope

This study provides a comprehensive analysis of oncology biomarkers on a global basis. It aims to offer a range of information, from detailed market analyses within cancer types to overall industry trends, to quantify and qualify the market for products and services in the oncology biomarkers segment. Current and projected market forecasts during the forecast period (2023 to 2028) are discussed. Figures for 2023 are estimated, except where actual results have been reported.

This report includes forecasts by biomarker type, cancer type, application, and region from 2023 through 2028. The report also includes an analysis of leading and emerging competitors in the current worldwide oncology biomarkers market. The competitive environment is examined with a particular focus on how new products and technologies influence the current standard of care.

Frequently Asked Questions (FAQs)

The global oncology biomarker market was valued at $15.5 billion in 2022. The market is projected to reach $35.2 billion in 2028, growing at a CAGR of 14.9% during the forecast period.
Biomarkers have attained immense significance in the cancer care spectrum (risk assessment, screening, diagnosis, therapeutic decisions, and monitoring). The market is propelled by intensive research efforts in the field of cancer, aimed toward discovering new treatments and diagnostic methods for screening and disease diagnosis. Moreover, Next generation sequencing (NGS) and gene expression profiling methods in proteomic technologies have led to the rising adoption of biomarkers in the clinical management of cancer patients. Oncology is the focus of major precision medicine trials and studies. There is a lot of interest from pharmaceutical developers in the use of biomarkers in cancer drug development. The creation of companion diagnostic (CDx) tests can improve the quality of treatment and boost this market.
An in-depth analysis of the global oncology biomarkers market, including historical data and market projection on sales by biomarker type, application, cancer type, and region.
North America has the highest market share in the oncology biomarkers market.
F. Hoffmann-La Roche AG, ThermoFisher Scientific, Abbott, Bio-Rad Laboratories, bioMérieux, Siemens Healthineers, Shimadzu Corp., Merck KGaA, Leica Biosystems (part of Danaher Corp.), Myriad Genetics Laboratories Inc., Qiagen N.V., Guardant Health, Illumina Inc., Sysmex Corp., Laboratory Corporation of America Holdings, and others.

Analyst Credentials

BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.

Report Synopsis

Report Metrics Details
Base year considered 2022
Forecast period considered 2023-2028
Base year market size $15.5 billion
Market size forecast $35.2 billion
Growth rate CAGR of 14.9% for the forecast period of 2023-2028
Units considered $ Millions
Segments covered Biomarker Type, Application, Cancer Type
Regions covered North America, Europe, Asia-Pacific, Rest of the World (RoW)
Countries covered U.S., Canada, Germany, France, U.K., Italy, Spain, Switzerland, Denmark, Norway, Poland, Belgium, Austria, Netherlands, Sweden, Russia, China, Japan, India, Australia, South Korea, New Zealand, Taiwan, Singapore, Malaysia, Thailand, Philippines, Indonesia, Latin America, Middle East and Africa
Key Market Drivers
  • Rising Incidence of Cancer
  • Increasing Use of Biomarkers in Drug Discovery and Development
  • Developments in Analytical Technologies and Assay Methods
  • Increased Availability and Ease of Biomarker Testing
  • Support from Regulatory Agencies
Companies studied
  • AGENDIA INC.
  • ABBOTT
  • AGILENT TECHNOLOGIES INC.
  • BIOCARTIS NV
  • BIOMERIEUX SA
  • BIO-RAD LABORATORIES INC.
  • BECTON, DICKINSON AND CO.
  • EXACT SCIENCES CORP.
  • F. HOFFMANN-LA ROCHE LTD.
  • GUARDANT HEALTH INC.
  • HOLOGIC INC.
  • ILLUMINA INC.
  • LEICA BIOSYSTEMS
  • MERCK KGAA
  • MYRIAD GENETICS INC.
  • QIAGEN
  • SIEMENS HEALTHINEERS AG
  • THERMO FISHER SCIENTIFIC INC.
  • VERACYTE INC.

Table of Contents

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Title/Chapter NamePagesMember Price
Full Report: Oncology Biomarkers: Global Markets186Free
Chapter- 1: Introduction6Free
Chapter- 2: Summary and Highlights2Free
Chapter- 3: Market Outlook1Free
Chapter- 4: Market and Technology Background9Free
Chapter- 5: Market Dynamics10Free
Chapter- 6: Market Breakdown by Biomarker Type20Free
Chapter- 7: Market Breakdown by Application20Free
Chapter- 8: Market Breakdown by Cancer Type32Free
Chapter- 9: Market Breakdown by Region16Free
Chapter- 10: Impact of COVID-193Free
Chapter- 11: Emerging Trends and Technologies in the Market7Free
Chapter- 12: Competitive Landscape7Free
Chapter- 13: Company Profiles50Free
Chapter- 14: Appendix: Acronyms3Free
Oncology Biomarkers: Global Markets

Single User License: $5500

Become a Member

Already a member? Login to access this report free.

Have a Question? Ask Us.

Why BCC Research.?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
Custom Research

Need a custom data table, graph or complete report? Tell us more.

RELATED REPORTS